Groups Similar Look up By Text Browse About



Similar articles
Article Id Title Prob Score Similar Compare
220990 ARSTECHNICA 2021-11-24:
Elizabeth Holmes says she forged pharma reports—for all the right reasons
1.000 Find similar Compare side-by-side
220826 THEVERGE 2021-11-23:
Elizabeth Holmes admitted to a key part of the case against her
0.762 0.603 Find similar Compare side-by-side
220972 ARSTECHNICA 2021-11-23:
Elizabeth Holmes throws scientists under the bus
0.160 0.496 Find similar Compare side-by-side
220875 ARSTECHNICA 2021-11-22:
Wealth and privilege allowed Elizabeth Holmes to start Theranos
0.020 0.459 Find similar Compare side-by-side
221023 ZDNET 2021-11-23:
Life360 to acquire Tile for $205 million
0.269 Find similar Compare side-by-side
221038 ZDNET 2021-11-21:
Conglomerates are dead, but tech giants are conglomerates in training
0.261 Find similar Compare side-by-side
220849 TECHREPUBLIC 2021-11-24:
Be wary of trusting algorithms in volatile markets
0.261 Find similar Compare side-by-side
220909 ARSTECHNICA 2021-11-22:
Activision Blizzard CEO Bobby Kotick says he would consider stepping down
0.258 Find similar Compare side-by-side
220876 VENTUREBEAT 2021-11-21:
Report: Only 16% of orgs rank employee retention as top priority
0.255 Find similar Compare side-by-side
220914 TECHREPUBLIC 2021-11-23:
How to identify social media misinformation and protect your business
0.254 Find similar Compare side-by-side
221056 ZDNET 2021-11-22:
Siemens' new system helps companies track emissions across the supply chain
0.254 Find similar Compare side-by-side
221137 THEVERGE 2021-11-24:
Pinterest settles lawsuit that alleged racial and gender discrimination
0.248 Find similar Compare side-by-side
220947 ARSTECHNICA 2021-11-23:
Are scientists less prone to motivated reasoning?
0.245 Find similar Compare side-by-side
220829 THEVERGE 2021-11-23:
Hawkeye starts out strong because it doesn’t take itself too seriously
0.245 Find similar Compare side-by-side
220838 VENTUREBEAT 2021-11-23:
The long-awaited evolution of learning labs to meet a cloud-centric world (VB Live)
0.242 Find similar Compare side-by-side
220942 ZDNET 2021-11-24:
Robo-debt inquiry wants Reynolds to face Senate if she continues to refuse to cooperate
0.234 Find similar Compare side-by-side
220842 ARSTECHNICA 2021-11-24:
“NFT” picked as word of the year—deal with it
0.233 Find similar Compare side-by-side
220938 TECHREPUBLIC 2021-11-24:
How to use Bash associative arrays
0.231 Find similar Compare side-by-side
221174 ZDNET 2021-11-24:
NSW government clamps down on apartment building defects using blockchain and AI
0.222 Find similar Compare side-by-side
221060 ZDNET 2021-11-22:
Forget Google. How Microsoft can deliver better mobile support and Android experience
0.222 Find similar Compare side-by-side
220984 ZDNET 2021-11-23:
TIO wants telcos to have 24-hour fraud hotline
0.221 Find similar Compare side-by-side
220835 VENTUREBEAT 2021-11-23:
ALSP Orchid Acquisition Corporation I Announces $172.5 Million Initial Public Offering
0.220 Find similar Compare side-by-side
220910 THEVERGE 2021-11-23:
Audi RS E-tron GT review: electric extravagance
0.212 Find similar Compare side-by-side
221154 ZDNET 2021-11-26:
From drones to virtual reality: How golf is now a favourite testing ground for new tech
0.212 Find similar Compare side-by-side
221050 ZDNET 2021-11-22:
Jane Hume says cryptocurrency not a fad despite RBA and ASIC warnings
0.209 Find similar Compare side-by-side

1

ID: 220990

URL: https://arstechnica.com/tech-policy/2021/11/elizabeth-holmes-says-she-forged-pharma-reports-for-all-the-right-reasons/

Date: 2021-11-24

Elizabeth Holmes says she forged pharma reports—for all the right reasons

Former CEO blames COO Balwani for overly optimistic financial projections. Elizabeth Holmes spent over six hours on the stand yesterday, trying to make the case that, while mistakes were made, she never meant to defraud anyone. Its an argument that appears to rely heavily on nuance and emotion. When Holmes handed investors forged reports, did she mean to deceive them? When she shared overly optimistic financial projections, was she merely relying on the work of others? When she declined to tell investors that Theranos was using third-party devices to run blood tests—contrary to her companys carefully cultivated public image —was she being duplicitous or merely protecting her companys hard-won trade secrets? How the jury interprets Holmes answers will likely depend on her performance under cross-examination, which has yet to begin. But her testimony yesterday attempted to paint an image of a conscientious executive who was misguided at key decision points. She and her attorneys dropped hints that, at each of those points, her intentions were noble, ranging from selflessness to trust, respect, and even motherly protectiveness. This work was done in partnership with these companies and I was trying to convey that, she testified. Did she realize that other people would believe that the pharmaceutical companies, not Theranos, were the authors of the report, Downey asked her. No, she said. Ive heard that testimony in this case, and I wish Id done it differently. Another bombshell came when she placed the blame for rosy financial projections squarely with Ramesh Sunny Balwani, Theranos COO and her boyfriend at the time. The projections came from financial models he created, Holmes said, which were heavily influenced by assumptions about how quickly Theranos could roll out its testing services in Walgreens stores. The startup had a deal with the drug store to put its proprietary devices at some 3,000 locations. While she trusted Balwani with the financial projections, Holmes said that she put Vice President Daniel Young in charge of the Walgreens rollout. He had skillsets in modeling and data, and we wanted to apply them, she told the court. When that rollout faltered, it wasnt because Theranos' technology wasnt up to snuff, she said, but because Walgreens' new management got cold feet, thinking they would run into regulatory trouble if they put a Theranos device in every store. Our lawyers had different opinions, but we agreed to do what Walgreens wanted, she said.